Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$37.26 USD

37.26
5,806,710

+1.04 (2.87%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $37.26 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

by Zacks Equity Research

Exelixis obtains FDA nod for label expansion of lead drug Cabometyx for neuroendocrine tumors.

Zacks Equity Research

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

by Zacks Equity Research

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.

Zacks Equity Research

Here's Why Exelixis (EXEL) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

by Zacks Equity Research

Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors have been highlighted in this Screen of The Week article.

Urmimala Biswas headshot

4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

by Urmimala Biswas

Here are four PEG-based GARP picks, GILD, EXEL, SYF and TAP, which qualify our screening criteria.

Zacks Equity Research

EXEL or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Ekta Bagri headshot

Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?

by Ekta Bagri

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.

Zacks Equity Research

International Markets and Exelixis (EXEL): A Deep Dive for Investors

by Zacks Equity Research

Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Zacks Equity Research

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus

by Zacks Equity Research

Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.

Zacks Equity Research

Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 7.84% and 0.65%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zoetis Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

ZTS' higher companion animal product sales are likely to have driven revenues in fourth-quarter 2024 in both the United States and International segments.

Zacks Equity Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Zacks Equity Research

Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports fourth-quarter 2024 results.

Zacks Equity Research

Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JHSC

Zacks Equity Research

Zacks.com featured highlights include Pilgrim's Pride, Exelixis, Synchrony and United Airlines

by Zacks Equity Research

Pilgrim's Pride, Exelixis, Synchrony and United Airlines have been highlighted in this Screen of The Week article.